[Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
The purpose of this study was to assess the safety of TS-1 when used as adjuvant chemotherapy after surgical resection of advanced stomach cancer. The subjects were 20 patients with stage III or IV, curability B resected gastric cancer. The methods consisted of analysis of background factors, assessment of the administration and dosage of TS-1, and associations with adverse reactions. Mean age was 62.8 years, and the histological type was differentiated in 7 cases and undifferentiated in 13 cases. There were 4 stage IIIA cases, 10 stage IIIB cases, and 6 stage IV cases, and the extent of gastric resection consisted of gastrectomy in 8 cases and total gastrectomy in 12 cases. TS-1 administration was started an average of 57 days postoperatively. The dosage regimen was 4 weeks on and 2 weeks off in 10 cases, and different regimens were used in the other 10 cases. The dose of TS-1 was the recommended dose in 9 cases and a reduced dose in 11 cases, and the mean number of courses was 2.8. Adverse reactions occurred in a total of 14 cases. Digestive system toxicity developed in 5 cases and hematological toxicity in 12. No grade 3 or 4 toxicity was observed. Treatment could be continued in 18 cases. The occurrence of adverse reactions tended to be concentrated immediately after administration of TS-1. TS-1 was safely used as adjuvant chemotherapy after resection of advanced stomach cancer.